Pascal Bamford - 08 Jul 2025 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
Chief Clinical Officer
Signature
/s/ Pascal Bamford
Issuer symbol
AKYA
Transactions as of
08 Jul 2025
Net transactions value
$0
Form type
4
Filing time
10 Jul 2025, 20:39:13 UTC
Previous filing
02 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BAMFORD PASCAL Chief Clinical Officer C/O AKOYA BIOSCIENCES, INC., 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH /s/ Pascal Bamford 10 Jul 2025 0002035474

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKYA Common Stock Other -9,488 -4.6% 196,250 08 Jul 2025 Direct F1, F2
transaction AKYA Common Stock Other -196,250 -100% 0 08 Jul 2025 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Employee Stock Option (Right to Buy) Other $0 -150,000 -100% $0.000000 0 08 Jul 2025 Common Stock 150,000 $13.34 Direct F4, F5
transaction AKYA Employee Stock Option (Right to Buy) Other $0 -25,000 -100% $0.000000 0 08 Jul 2025 Common Stock 25,000 $12.30 Direct F4, F5
transaction AKYA Employee Stock Option (Right to Buy) Other $0 -15,000 -100% $0.000000 0 08 Jul 2025 Common Stock 15,000 $5.96 Direct F4, F5
transaction AKYA Employee Stock Option (Right to Buy) Other $0 -50,000 -100% $0.000000 0 08 Jul 2025 Common Stock 50,000 $5.35 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Pascal Bamford is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.
F2 In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement.
F3 Represents aggregate share value of Issuer restricted stock units ("RSU") unvested immediately prior to the Closing Date (each individual RSU, a "Rollover RSU"). On the Closing Date, each Rollover RSU was automatically converted into the right to receive the Per Share Merger Consideration for each share of Issuer common stock subject to such Rollover RSU upon vesting, subject to the same terms and conditions of each Rollover RSU in effect immediately prior to the effectiveness of the Merger.
F4 Disposition of options pursuant to Merger Agreement.
F5 Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.